A new lab assay accurately predicts how fast peptide drugs break down at the injection site, explaining why drugs like semaglutide last a week while others need daily dosing.
Injection-site breakdownEnzymatic degradation at the subcutaneous injection site is a major determinant of how much peptide drug actually reaches your bloodstream
What the researchers found
Researchers developed and validated a lab assay (SCiMetPep) that predicts how quickly peptide drugs break down at the subcutaneous injection site — a major factor in how much drug actually reaches the bloodstream. Using tissue from humans, rats, and minipigs, the assay measured degradation rates and identified the specific enzymatic breakdown products for insulin, lixisenatide, exenatide, liraglutide, and semaglutide.
The in vitro results matched published in vivo data well. When applied to a series of structurally related peptides, injection-site metabolic stability correlated with bioavailability — confirming that what happens to a peptide right at the injection site is a major determinant of how much drug your body actually absorbs. The assay can identify which parts of a peptide are vulnerable to breakdown, guiding chemists to design more stable versions.
Why it matters
When you inject a peptide drug under your skin, enzymes in the subcutaneous tissue start breaking it down immediately — before it even reaches your bloodstream. This is why semaglutide (highly stable) works as a once-weekly injection while some other peptides require daily or multiple daily doses. Having a lab test that predicts this breakdown early in drug development means researchers can identify stability problems and engineer solutions before expensive animal and human testing begins.
The numbers in context
Validated with 5 known peptides (insulin, lixisenatide, exenatide, liraglutide, semaglutide) · human, rat, and minipig SC tissue · half-life + metabolite identification · good correlation between SC stability and bioavailability
How the study worked
The researchers developed the SCiMetPep assay using subcutaneous tissue homogenate supernatant from three species: human, Sprague-Dawley rat, and Göttingen minipig. Peptides were incubated with the tissue extracts and analyzed by liquid chromatography-high resolution mass spectrometry. The method measures both the degradation half-life of the parent peptide and identifies specific metabolites from enzymatic proteolysis. Validation was performed by comparing in vitro results to published in vivo pharmacokinetic data for five well-characterized peptide drugs.
Who was studied
Not applicable (in vitro assay validated with tissue from humans, rats, and minipigs)
What this study cannot tell us
The assay uses tissue homogenates rather than intact tissue, which may not fully replicate the complexity of in vivo subcutaneous absorption including blood flow, lymphatic drainage, and tissue architecture. The validation was limited to five known peptides, though the correlation with in vivo data was good. Species differences in enzyme activity mean results from one species may not perfectly predict another. The assay predicts metabolic stability but not other factors affecting bioavailability like aggregation or tissue binding.
How to read the evidence
This is a well-designed method development study validated against five FDA-approved peptide drugs with good correlation to published in vivo data. The 'Moderate' grade reflects that this is a preclinical tool validation rather than a clinical trial.
When this study was published
Published in 2018, this study is relevant to the ongoing development of subcutaneous peptide therapeutics. The assay methodology and the validated reference peptides (including semaglutide) remain current.
The bigger picture
The difference between a once-weekly injection and a twice-daily one often comes down to how stable the peptide is at the injection site. This assay gives drug developers a fast, reliable way to test stability early in the design process. As the peptide therapeutics market grows — with GLP-1 agonists alone generating tens of billions in revenue — tools like this help accelerate the development of next-generation peptide drugs with better dosing profiles.
Questions still open
- Could this assay be used to predict the stability of compounded or modified peptides from non-pharmaceutical sources?
- What specific chemical modifications (like those in semaglutide) confer the greatest protection against injection-site degradation?
- How do factors like injection depth, volume, and body composition affect peptide stability beyond what this assay captures?
Common questions
Why does semaglutide last a whole week while insulin needs to be injected daily or more?
How does this assay help make better peptide drugs?
Read the original research
A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides.
Journal of pharmaceutical and biomedical analysis, 159, 449-458
Citation
Esposito, Simone; de Leonibus, Maria Lucia; Ingenito, Raffaele; Bianchi, Elisabetta; Orsatti, Laura; Monteagudo, Edith. (2018). A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides.. Journal of pharmaceutical and biomedical analysis, 159, 449-458. https://doi.org/10.1016/j.jpba.2018.07.009